Skip Navigation

Annals of Oncology 2006 17(7):1033; doi:10.1093/annonc/mdl160
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

in this issue

in this issue

The first 10% of the full text of this article appears below.


   Docetaxel plus carboplatin in advanced NSCLC
 
Non-small-cell lung cancer (NSCLC) remains the leading cause of cancer-related death throughout Europe and the United States and is responsible for approximately 1 million deaths worldwide each year. Phase III studies have suggested that NSCLC patients treated with cisplatin-docetaxel may have higher response rates and better survival compared with other platinum-based regimens. In this issue, Booton et al. report the . . . [Full Text of this Article]


   Stem cell transplantation in renal cancer
 

   Topotecan salvage therapy in primary CNS lymphoma
 

   Psychological impact of cancer in parents
 

   Quote
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?